Amine Hila, MD
Gastroenterology · Binghamton, NYNPI 1619055845
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,400 of the $8,245 with a category attached, or 77.6%. AbbVie accounts for 87.6% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $7,661 and has fallen 99.7% since, to $22 in 2024.
Across 100 payments — averaging $82.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Johnson & Johnson$202
- Takeda Pharmaceuticals U.S.A., Inc.$196
- Pfizer$167
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$136
- E.r. Squibb & Sons, L.L.C.$107
- plus $218 from 8 others
Across 49 payments — averaging $1804.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$74K
- Ironwood Pharmaceuticals, Inc$14K
What the payments were for
- Consulting fees$160%
- Speaking & faculty fees$6,40078%
- Travel & lodging$941%
- Food & beverage$1,70821%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $7,219 |
| Johnson & Johnson(2 entities) | 13 | $202 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $196 |
| Pfizer | 14 | $167 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $136 |
| E.r. Squibb & Sons, L.L.C. | 1 | $107 |
| Intercept Pharmaceuticals, Inc. | 7 | $103 |
| UCB, Inc. | 1 | $23 |
| QOL Medical, LLC | 1 | $18 |
| Concordia Pharmaceuticals Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $16 |
| Merck | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,245 in reported general payments places this provider in the 75th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 29 | $647 |
| Esomeprazole Magnesium | 13 | $582 |
| Famotidine | 13 | $234 |
| Omeprazole | 22 | $233 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Binghamton
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.